Moxifloxacin: a comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae
- PMID: 10052905
- DOI: 10.1093/jac/42.6.803
Moxifloxacin: a comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae
Abstract
Two hundred representative isolates, including 26 strains of Streptococcus pneumoniae with intermediate resistance to penicillin, were selected from a collection obtained from blood cultures of patients with bacteraemic pneumococcal pneumonia. The MICs of moxifloxacin (BAY 12-8039), grepafloxacin, sparfloxacin, levofloxacin, ofloxacin, ciprofloxacin, erythromycin, tetracycline and penicillin G were determined by a standard agar dilution technique. Moxifloxacin had the highest in-vitro activity against S. pneumoniae (MIC90 = 0.25 mg/L; MIC range 0.06-0.25 mg/L). The MIC90 values were one dilution lower than those obtained with sparfloxacin and grepafloxacin, three dilutions lower than those obtained with levofloxacin, and four dilutions lower than those of ofloxacin and ciprofloxacin.
Similar articles
-
A comparative study of the in-vitro activity of levofloxacin against Streptococcus pneumoniae.J Antimicrob Chemother. 1999 Jun;43 Suppl C:5-8. doi: 10.1093/jac/43.suppl_3.5. J Antimicrob Chemother. 1999. PMID: 10404330
-
Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.J Antimicrob Chemother. 2001 Jun;47(6):875-7. doi: 10.1093/jac/47.6.875. J Antimicrob Chemother. 2001. PMID: 11389122
-
In vitro activity of gemifloxacin against Streptococcus pneumoniae isolates in Germany.Chemotherapy. 2001 Mar-Apr;47(2):104-9. doi: 10.1159/000048508. Chemotherapy. 2001. PMID: 11173811
-
Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity.Clin Infect Dis. 2001 Mar 15;32 Suppl 1:S22-9. doi: 10.1086/319372. Clin Infect Dis. 2001. PMID: 11249825 Review.
-
Efficacy and tolerability of moxifloxacin in the treatment of acute bacterial sinusitis caused by penicillin-resistant Streptococcus pneumoniae: a pooled analysis.Clin Ther. 2004 Feb;26(2):224-31. doi: 10.1016/s0149-2918(04)90021-5. Clin Ther. 2004. PMID: 15038945 Review.
Cited by
-
A critical review of the fluoroquinolones: focus on respiratory infections.Drugs. 2002;62(1):13-59. doi: 10.2165/00003495-200262010-00002. Drugs. 2002. PMID: 11790155 Review.
-
Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.Drugs. 2000 Jan;59(1):115-39. doi: 10.2165/00003495-200059010-00010. Drugs. 2000. PMID: 10718103 Review.
-
Once-daily moxifloxacin therapy for community-acquired pneumonia in general practice : evidence from a post-marketing surveillance study of 1467 patients.Clin Drug Investig. 2004;24(8):441-8. doi: 10.2165/00044011-200424080-00002. Clin Drug Investig. 2004. PMID: 17523704
-
Efficacy and tolerability of moxifloxacin in 2338 patients with acute exacerbation of chronic bronchitis.Clin Drug Investig. 2003;23(1):1-10. doi: 10.2165/00044011-200323010-00001. Clin Drug Investig. 2003. PMID: 23319088
-
Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.Antimicrob Agents Chemother. 2000 Oct;44(10):2645-52. doi: 10.1128/AAC.44.10.2645-2652.2000. Antimicrob Agents Chemother. 2000. PMID: 10991838 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical